PURPOSE:Chemoradiotherapy (CRT)-induced oral mucositis (OM) adversely affects a patient's oral functions and quality of life (QOL). Low-level laser therapy (LLLT) showed some preventive and curative effects against clinically reported objective measures of OM in few trials including our recently published study. There is dearth of evidence regarding the effects of LLLT on patient's subjective experience of OM and QOL. Hence, we did this study to evaluate the effects of LLLT on a patient's reported measures of OM and QOL in head and neck cancer (HNC) patients receiving CRT. METHODS: This triple blinded study randomized 220 HNC patients scheduled for CRT (three weeklyCisplatin + RT = 66 Gray (2 Gy/session), five fractions/week for 6.5 weeks, total 33 fractions) into laser (110) and placebo (110) groups. The laser group received LLLT (Technomed Electronics Advanced Laser Therapy 1000, He-Ne, λ = 632.8 nm, power density = 24 mW/cm(2), dosage = 3.0 J at each point, total dose/session = 36-40 J, spot size 1 cm(2), irradiation time/point 125 s) before each radiation session, while the placebo group did not receive laser therapy. Methodology was similar to our recently published study (Gautam et al. Radiother Oncol 104:349-354, 2012). In this part of our study, a blinded assessor collected subjective outcomes of the patient's reported measures of OM using Oral Mucositis Weekly Questionnaire-Head and Neck (OMWQ-HN) and QOL using Functional Assessment of Cancer Treatment-Head and Neck (FACT-HN) Questionnaire. Data were analyzed using repeated measure ANOVA through general linear model. Statistical significance was kept at p < 0.05. RESULTS: Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients. Also, a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed. CONCLUSIONS:LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
RCT Entities:
PURPOSE: Chemoradiotherapy (CRT)-induced oral mucositis (OM) adversely affects a patient's oral functions and quality of life (QOL). Low-level laser therapy (LLLT) showed some preventive and curative effects against clinically reported objective measures of OM in few trials including our recently published study. There is dearth of evidence regarding the effects of LLLT on patient's subjective experience of OM and QOL. Hence, we did this study to evaluate the effects of LLLT on a patient's reported measures of OM and QOL in head and neck cancer (HNC) patients receiving CRT. METHODS: This triple blinded study randomized 220 HNC patients scheduled for CRT (three weekly Cisplatin + RT = 66 Gray (2 Gy/session), five fractions/week for 6.5 weeks, total 33 fractions) into laser (110) and placebo (110) groups. The laser group received LLLT (Technomed Electronics Advanced Laser Therapy 1000, He-Ne, λ = 632.8 nm, power density = 24 mW/cm(2), dosage = 3.0 J at each point, total dose/session = 36-40 J, spot size 1 cm(2), irradiation time/point 125 s) before each radiation session, while the placebo group did not receive laser therapy. Methodology was similar to our recently published study (Gautam et al. Radiother Oncol 104:349-354, 2012). In this part of our study, a blinded assessor collected subjective outcomes of the patient's reported measures of OM using Oral Mucositis Weekly Questionnaire-Head and Neck (OMWQ-HN) and QOL using Functional Assessment of Cancer Treatment-Head and Neck (FACT-HN) Questionnaire. Data were analyzed using repeated measure ANOVA through general linear model. Statistical significance was kept at p < 0.05. RESULTS: Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients. Also, a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed. CONCLUSIONS: LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
Authors: N Pourreau-Schneider; M Soudry; J C Franquin; H Zattara; P M Martin; G Ciais; M Namer; M Schneider; P Chauvel; F Demard Journal: J Natl Cancer Inst Date: 1992-03-04 Impact factor: 13.506
Authors: Joel B Epstein; Jennifer L Beaumont; Clement K Gwede; Barbara Murphy; Adam S Garden; Ruby Meredith; Quynh-Thu Le; David Brizel; John Isitt; David Cella Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Daniel J Givens; Lucy Hynds Karnell; Anjali K Gupta; Gerald H Clamon; Nitin A Pagedar; Kristi E Chang; Douglas J Van Daele; Gerry F Funk Journal: Arch Otolaryngol Head Neck Surg Date: 2009-12
Authors: Jennifer A Kushner; Herenia P Lawrence; Irit Shoval; Thomas L Kiss; Gerald M Devins; Linda Lee; Howard C Tenenbaum Journal: J Can Dent Assoc Date: 2008-02 Impact factor: 1.316
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: G Ciais; M Namer; M Schneider; F Demard; N Pourreau-Schneider; P M Martin; M Soudry; J C Franquin; H Zattara Journal: Bull Cancer Date: 1992 Impact factor: 1.276
Authors: Yehuda Zadik; Praveen R Arany; Eduardo Rodrigues Fregnani; Paolo Bossi; Héliton Spindola Antunes; René-Jean Bensadoun; Luiz Alcino Gueiros; Alessandra Majorana; Raj G Nair; Vinisha Ranna; Wim J E Tissing; Anusha Vaddi; Rachel Lubart; Cesar Augusto Migliorati; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Stephen Rajan Samuel; Arun G Maiya; Donald J Fernandes; Vasudeva Guddattu; P U Prakash Saxena; Jestina Rachel Kurian; Po-Ju Lin; Karen M Mustian Journal: Support Care Cancer Date: 2019-03-27 Impact factor: 3.603
Authors: M Gobbo; G Ottaviani; G Perinetti; F Ciriello; A Beorchia; M Giacca; R Di Lenarda; K Rupel; G Tirelli; S Zacchigna; M Biasotto Journal: Support Care Cancer Date: 2014-02-20 Impact factor: 3.603